Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
University Foot and Ankle Foundation
Modality
protein_peptide
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT03978234CT.gov Evaluating the Safety and Effect of abobotulinumtoxinA in the Gastrocnemius Muscle to Improve Equinus and Plantar Fasciitis Pain | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Plantar Fasciitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Abobotulinumtoxina (this asset) | University Foot and Ankle Foundation | P2 | CC · 47 |
| Dehydrated Human Amnion/Chorion Membrane (Dhacm) | MiMedx Group, Inc. | P3 | BBB |
| Acetylcysteine | University of Arizona | P2 | CCC |
Other indications for Abobotulinumtoxina
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Compartment Syndrome | — | P4 | B · 56 |
| Spastic Cerebral Palsy | — | P2 | CC · 47 |
| Multiple Sclerosis | — | P3 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Abobotulinumtoxina in Plantar Fasciitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/abobotulinumtoxina-plantar-fasciitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →